LENSAR (NASDAQ:LNSR – Get Rating) is set to announce its earnings results before the market opens on Thursday, March 16th. Individual interested in participating in the company’s earnings conference call can do so using this link.
LENSAR Stock Performance
NASDAQ LNSR opened at $3.27 on Tuesday. LENSAR has a 52-week low of $2.15 and a 52-week high of $8.80. The company has a 50-day simple moving average of $2.92 and a 200 day simple moving average of $3.94. The company has a market capitalization of $36.04 million, a PE ratio of -1.53 and a beta of -0.24.
Hedge Funds Weigh In On LENSAR
A number of large investors have recently modified their holdings of the company. Ancora Advisors LLC purchased a new position in shares of LENSAR during the first quarter worth approximately $85,000. Charles Schwab Investment Management Inc. bought a new position in LENSAR in the 1st quarter worth about $86,000. State Street Corp raised its position in LENSAR by 5.1% in the 1st quarter. State Street Corp now owns 34,791 shares of the company’s stock worth $257,000 after buying an additional 1,697 shares during the last quarter. DCF Advisers LLC raised its position in LENSAR by 2.6% in the 1st quarter. DCF Advisers LLC now owns 287,023 shares of the company’s stock worth $2,124,000 after buying an additional 7,235 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of LENSAR by 6.4% during the 1st quarter. Vanguard Group Inc. now owns 433,293 shares of the company’s stock valued at $3,207,000 after purchasing an additional 26,117 shares during the last quarter. 54.43% of the stock is currently owned by institutional investors.
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
- Get a free copy of the StockNews.com research report on LENSAR (LNSR)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.